NC-LENOVO
Lenovo will host its annual global innovation event, Tech World , virtually on September 8, marking the 6th consecutive year of the event. This year’s visionary showcase will focus on Lenovo’s transformation and new solutions for the next reality – a new era where technologies for hybrid working and living environments and new business models for delivering technology solutions globally are emerging as the world faces fast-paced, unprecedented change and a growing demand for smarter technology for all.
Tech World will feature exclusive virtual sessions, including a headline keynote delivered by Lenovo Chairman and CEO, Yuanqing Yang, who will offer unique insights on how Lenovo is transforming its business and solutions for the next reality and how the world will live, learn, connect, and work over the course of the next year and beyond. Attendees will hear messages from Lenovo Chief Technology Officer, Dr. Yong Rui, Microsoft Chairman and CEO Satya Nadella, Deloitte Global CEO, Punit Renjen, SAP Chief Executive Officer, Christian Klein, and many other global tech and business leaders.
Tech World sessions will also highlight IT industry leaders who are paving the way for hybrid work and growing the role of smarter technology in shaping the next reality. The leaders of Lenovo’s three main business groups – including its world leading PC and device business (Lenovo IDG President Luca Rossi), its rapidly growing datacenter infrastructure group (Lenovo ISG President Kirk Skaugen), and its brand new solutions and services organization (Lenovo SSG President Ken Wong) – will also be joined by industry experts and special guests to talk about the future tech landscape and introduce a range of new solutions, initiatives and devices related to Lenovo’s edge to cloud portfolio, the evolution of the ‘as-a-service’ model, AI and analytics, green tech, education tech, and gaming and entertainment.
Tech World is a streamed and on-demand event across multiple time zones and delivered in eight languages (Chinese, English, French, German, Japanese, Korean, Portuguese, Spanish). This event is free to everyone. To register and see a full agenda of speakers, visit here.
Watch highlights from previous Tech World events:
Tech World 2015 – Beijing, Tech World 2016 – San Francisco, Tech World 2017 – Shanghai, Tech World 2018 – Beijing, Tech World 2019 – Beijing, Tech World 2020 – Virtual.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005268/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation21.10.2025 12:00:00 CEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and leader in sustainable product innovation, to accelerate the development of IFF’s Designed Enzymatic Biomaterials™ technology platform and create next-generation enzyme technologies for fabric, dish and personal care as well as industrial cleaning applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021911702/en/ Photo credit: IFF This collaboration brings together two industry leaders with a shared vision: to develop high-performance, sustainable solutions that meet evolving consumer and market demands. By combining advanced chemical capabilities and expertise in biotechnology and protein engineering from IFF and BASF, the partnership aims to deliver breakthrough solutions at scale that enhance cleaning performance, imp
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 11:12:00 CEST | Press release
This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression of progressive supranuclear palsy (PSP)The study is being conducted across 44 centers in the European Union, the United Kingdom, and the United StatesThe study reinforces Ferrer’s commitment to researching and developing transformative therapeutic solutions for people with rare neurological diseases Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 10:51:00 CEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 10:00:00 CEST | Press release
Investment in European infrastructure strengthens Impartner’s EMEA operations and commitment to data security and regional growth Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azu
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 10:00:00 CEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom